GlassScriptPhysician profile
Ejaz U Kamboj
NPI 1396833810
$24,648.91
in general payments reported to CMS, 2019-2025
24 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,070 · 2020: $2,210 · 2021: $263 · 2022: $313 · 2023: $299 · 2024: $16K · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $16K · Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $15,963.94 |
| Food and Beverage | $829.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $16,114.04 | 2024 | Symplicity G3 |
| Angiodynamics, INC. | $4,822.62 | 2019-2020 | |
| Ge Healthcare | $2,058.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $219.60 | 2020-2023 | |
| Shockwave Medical, INC | $207.94 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astellas Pharma US INC | $198.71 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $185.22 | 2021-2023 | Verquvo |
| Abbott Laboratories | $162.19 | 2023-2025 | Mitraclip |
| Bard Peripheral Vascular, INC. | $102.15 | 2021-2023 | Venclose Maven Catheter |
| Silk Road Medical, INC. | $101.05 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $82.25 | 2019-2022 | |
| Novo Nordisk INC | $81.45 | 2023-2025 | Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $64.88 | 2020-2024 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $50.09 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $46.51 | 2025 | Amvuttra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.48 | 2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $20.00 | 2019 | |
| Bardy Diagnostics, INC. | $19.24 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.68 | 2019 | |
| Boston Scientific Corporation | $17.51 | 2023 | Varithena Administration Pack |
| Medicomp INC | $16.89 | 2020 | |
| Impulse Dynamics (USA) INC. | $16.50 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.91 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ejaz Kamboj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.